Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.67 |
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | CTSC | P53634 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 4/20 | 0.60 |
| ▸ | CPA1 | P15085 | 4/20 | 0.60 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30581399 | 1.00 | MME (0.67) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30581391 | 1.00 | MME (0.67) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL1329567 | 1.00 | MME (0.67) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL825577 | 1.00 | MME (0.67) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL7355800 | 1.00 | MME (0.67) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL14772130 | 0.97 | MME (0.63) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30862466 | 0.97 | MME (0.63) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL30862442 | 0.97 | MME (0.63) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL8082487 | 0.97 | MME (0.63) | MMEALPIPKMPTGS1XIAP | |
| SCHEMBL8082492 | 0.97 | MME (0.63) | MMEALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899240-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119390765-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-118772231-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2024163598-A2 | PEPTIDES COMPRISING THIOESTER GROUPS, INCLUDING DEPSIPEPTIDE THIOESTERS, METHODS OF MAKING, AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2024-08-08 | — | — | WO | claimed |
| US-3965260-A | Anti-inflammatory dipeptide | McArthur, John N. (CA) | 1976-06-22 | — | — | US | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4621826-A1 | METHOD FOR DETECTING NON-RACEMIC MIXTURES USING COLD ION PHOTOFRAGMENTATION MASS SPECTROMETRY | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| CN-119899240-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119390765-A | Kappa opioid receptor agonist and application thereof | 成都奥达生物科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20250011362-A1 | COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER | Clarity Pharmaceuticals Limited (AU) | 2025-01-09 | — | — | US | disclosed |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | disclosed |
| US-20220089646-A1 | A CYCLIC PEPTIDE | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-24 | — | — | US | disclosed |
| US-20080255033-A1 | Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7385025-B2 | Metallopeptide compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20050282739-A1 | Metallopeptide compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20040248212-A1 | Knockout identification of target-specific sites in peptides | PALATIN TECHNOLOGIES, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-3965260-A | Anti-inflammatory dipeptide | McArthur, John N. (CA) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | MME 824/4885ALPI 1473/4885PKM 1219/4885 |
| US-20220089646-A1 | A CYCLIC PEPTIDE | VIP, CALCA, CALCB | MME 273/4885ALPI 2058/4885PKM 3810/4885 |
| US-20080255033-A1 | Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds | MC1R, NGLY1, HM13 | MME 277/4885ALPI 2453/4885PKM 4677/4885 |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | VASP, PDE3A, PDE2A | MME 1103/4885ALPI 1924/4885PKM 1061/4885 |
| US-20250011362-A1 | COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER | FOLH1, PSMA2, PSMA3 | MME 184/4885ALPI 533/4885PKM 1232/4885 |
| US-20050282739-A1 | Metallopeptide compounds | MC1R, HM13, MC3R | MME 127/4885ALPI 2381/4885PKM 4736/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | MME 1103/4885ALPI 1924/4885PKM 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.